Clinical trial
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From…
NCT00150735 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00150735 |
|---|---|
| Title | Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy |
| Official title | A Multicenter, Double-blind, Randomized, Parallel Group, Positive-controlled Trial Comparing the Efficacy and Safety of Levetiracetam (1000 to 3000 mg/Day Oral b.i.d.) to Carbamazepine (400 to 1200 mg/Day Oral b.i.d.), Used as Monotherapy for up to a Maximum of 121 Weeks in Subjects (≥ 16 Years)… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Epilepsy |
| Intervention type | Drug |
| Interventions | LEVETIRACETAM |
| Enrollment | 580 |
| Start date | Jun 1, 2002 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 8, 2005 |
| Last update posted | Nov 26, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: